Medical Cannabis: Morocco’s First Export
A milestone in the Moroccan pharmaceutical industry. Cannaflex Morocco and the laboratory Sothema have announced the first export of a cannabis extract for medical use that is GMP (Good Manufacturing Practices) certified, derived from the local variety known as Beldia.
A product compliant with international pharmaceutical standards
This GMP certification guarantees that the product has been manufactured according to strict standards that cover:
- quality
- traceability
- safety
- packaging
These requirements meet the standards set by international health authorities and confirm the Moroccan product’s compliance with global pharmaceutical norms.
An active ingredient intended for medical treatments
Produced at Sothema’s facilities, this extract is intended to be used as a pharmaceutical active ingredient in medical treatments.
It occupies a high-value segment that is experiencing growth in the international pharmaceutical ingredient market.
A major advancement for the legal cannabis sector in Morocco
Beyond the commercial operation, this export represents a significant step for the Moroccan legal cannabis sector.
It confirms the Kingdom’s ability to:
- produce medical cannabis
- transform it according to international standards
- access global pharmaceutical markets
A strategic industrial and scientific cooperation
The project is based on collaboration among multiple stakeholders:
- Cannaflex, responsible for the supply chain
- Sothema, responsible for transformation under GMP standards
Sothema is also engaging in research and development activities in medical CBD/THC in partnership with:
- the Mohammed VI Center for Research and Innovation (CM6RI)
- the Mohammed VI Foundation for Science and Health (FM6SS)
This synergy reinforces Morocco’s positioning in pharmaceutical biotechnology.
A structured regulatory framework
This advancement is set within a strict regulatory framework governed by:
- the National Agency for Regulation of Cannabis Activities (ANRAC)
- the Moroccan Agency for Medicines and Health Products (AMMPS)
This system ensures control, safety, and compliance within the sector.
Pilot exports to multiple international markets
This first export follows several pilot operations conducted in 2025 to:
- Europe
- Australia
- South Africa
This confirms Morocco’s gradual rise in the global medical cannabis market.
Towards the industrialization of Moroccan medical cannabis
This step marks a live test of the Moroccan model and paves the way for a structured industrialization of the sector.
In this way, Morocco is progressively positioning itself as an emerging player in the international production of cannabis-derived pharmaceutical ingredients.
